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Review
Researchers evaluating toxicity and human 
exposure potential of engineered nano  ­
materials (ENMs) are challenged by rapid 
develop  ment of novel materials for new 
applications as the nano  technology industry 
drives forward. These materials can add sig­
nificant value to industrial or consumer prod­
ucts. ENMs have one or more components 
with at least one dimension in the range of 
1–1,000 nm. Components can include nano­
particles (NPs), nano  fibers and nano  tubes, 
nano  dots, nano  structured surfaces, or nano­
composites. Carbon nano  tubes (CNTs) and 
metal oxide NPs (two material types having 
the highest industrial production volumes) 
are used in plastics, catalysts, battery and fuel 
cell electrodes, solar cells, paints, coatings, etc. 
(Klaine et al. 2008). Nanoparticulate silver 
(Ag) has the greatest number of consumer 
product applications. Novel nano  material 
(NM) types continue to be synthesized based 
on the value they may add, often without 
evaluation of implications for human health, 
toxicity, environ  mental impact, or long­term 
sustainability. NMs, especially the ones made 
of metals, semi  conductors, and various inor­
ganic compounds, have the potential for post­
use risks to humans and the environment 
(National Nanotechnology Initiative 2008). 
These concerns need to be examined and 
addressed before the widespread adoption of 
nano  technologies (Oberdörster et al. 2005).
The U.S. Environmental Protection 
Agency (U.S. EPA) is beginning to evalu­
ate exposure and hazard potential of NMs 
and priori  tize them for further animal­based 
toxicological testing. Prioritization of NM 
classes and types for targeted testing is impor­
tant in the early stages of NM development. 
Currently, only a small portion of the thou­
sands of commonly used chemicals in the 
Toxic Substances Control Act (1976) inven­
tory (U.S. EPA 2004) have under  gone ani­
mal testing because of the high cost (millions 
of dollars) and long time frame (2–3 years) 
required per chemical (Judson et al. 2009). Of 
the unique chemicals (~ 10,000) the U.S. EPA 
is most concerned with, only a fraction have 
been evaluated for specific classes of toxicity 
(Judson et al. 2009). The ToxCast research 
program of the U.S. EPA was started in 2007 
and seeks to predict the potential toxicity of 
environmental chemicals based on in vitro bio­
activity profiling at minimal cost compared 
with full­scale animal testing (Dix et al. 2007). 
An initial set of approximately 300 chemicals 
(primarily pesticides) was tested in phase I of 
ToxCast in 467 high­throughput screening 
(HTS) biochemical and cell­based assays across 
nine technologies (Judson et al. 2010). A 
study has been initiated to evaluate the poten­
tial of ToxCast methods for screening NMs. 
A subset of ToxCast in vitro HTS cell­based 
assays will be run on NMs to produce similar 
bioactivity profiles and toxicity predictions. 
Most of the cell­based assays have an exposure 
time of 24 hr. Initial NM types to be evalu­
ated include single­walled carbon nano  tubes 
(SWCNTs) and multi  walled carbon nano  tubes 
(MWCNTs), along with Ag, titanium dioxide 
(TiO2), and gold (Au) NPs.
Design and conduct of ToxCast screen­
ing of NMs requires selection of testing con­
centrations, characterization of materials, and 
analysis of resulting HTS data. Selection of 
concentrations used for in vitro toxicity stud­
ies of NMs often lacks scientific justification, 
and concentrations are often chosen to be very 
high to ascertain a toxicological end point 
without consideration of real­world exposure 
(Oberdörster et al. 2005). Some research­
ers have used particle concentrations caus­
ing “overload” (Warheit et al. 2009), a dose 
where pulmonary clearance becomes severely 
impaired (Morrow 1988). Although high 
testing concentrations may be considered to 
ensure that NMs show bio  activity across the 
spectrum of assays evaluated, there is also a 
need for biologically relevant human expo­
sure information to facilitate interpretation of 
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Ba c k g r o u n d: Little justification is generally provided for selection of in vitro assay testing 
  concentrations for engineered nanomaterials (ENMs). Selection of concentration levels for hazard 
evaluation based on real-world exposure scenarios is desirable.
oBjectives: Our goal was to use estimates of lung deposition after occupational exposure to nano-
materials to recommend in vitro testing concentrations for the U.S. Environmental Protection 
Agency’s ToxCast™ program. Here, we provide testing concentrations for carbon nanotubes 
(CNTs) and titanium dioxide (TiO2) and silver (Ag) nanoparticles (NPs).
Me t h o d s : We reviewed published ENM concentrations measured in air in manufacturing and 
R&D (research and development) laboratories to identify input levels for estimating ENM mass 
retained in the human lung using the multiple-path particle dosimetry (MPPD) model. Model 
input parameters were individually varied to estimate alveolar mass retained for different particle 
sizes (5–1,000 nm), aerosol concentrations (0.1 and 1 mg/m3), aspect ratios (2, 4, 10, and 167), and 
exposure durations (24 hr and a working lifetime). The calculated lung surface concentrations were 
then converted to in vitro solution concentrations.
re s u l t s: Modeled alveolar mass retained after 24 hr is most affected by activity level and aerosol 
concentration. Alveolar retention for Ag and TiO2 NPs and CNTs for a working-lifetime (45 years) 
exposure duration is similar to high-end concentrations (~ 30–400 μg/mL) typical of in vitro testing 
reported in the literature.
co n c l u s i o n s: Analyses performed are generally applicable for providing ENM testing concen-
trations for in vitro hazard screening studies, although further research is needed to improve the 
approach. Understanding the relationship between potential real-world exposures and in vitro test 
concentrations will facilitate interpretation of toxicological results.
key w o r d s : ExpoCast, human particle deposition and retention, in vitro nanomaterial concentra-
tion, multiple-path particle dosimetry (MPPD), occupational exposure, ToxCast. Environ Health 
Perspect 119:1539–1546 (2011).  http://dx.doi.org/10.1289/ehp.1103750 [Online 25 July 2011]Gangwal et al.
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assay results (Cohen Hubal 2009). Authors of 
Toxicity Testing in the 21st Century: A Vision 
and a Strategy (National Research Council 
2007) noted that human exposure information 
is required to select doses for toxicity testing, 
facilitating development of environmentally 
relevant hazard information. 
Recognizing the critical need for expo­
sure information to inform chemical design, 
evalua  tion, and health risk management, the 
U.S. EPA ExpoCastTM program was initiated 
in 2010 to meet challenges posed by new tox­
icity testing approaches (Cohen Hubal et al. 
2010). The goal of ExpoCast is to advance 
characterization of exposure required to trans­
late findings in computational toxicology to 
information that can be directly used to sup­
port exposure and risk assessment. Combining 
information from ToxCast with information 
from ExpoCast will help the U.S. EPA priori­
tize NMs and chemi  cals for further evaluation 
based on potential risk to human health.
Human exposures to ENMs are likely to 
be higher for workers in occupational settings 
than for the general population, including 
consumers (Bergamaschi 2009), and may thus 
provide upper bounding estimates of exposure 
potentials. For consumers, the greatest expo­
sure to ENMs likely comes from products that 
are ingested or that come into intimate con­
tact with the body (Kessler 2011). Although 
ingestion and dermal exposures must also 
be considered during the product life cycle 
(manufacturing, usage, and disposal of EMNs) 
(Oberdörster et al. 2005; U.S. EPA 2010), 
inhalation may be the key route of human 
exposure in nano  technology manufacturing 
and R&D (research and development) facili­
ties (Bergamaschi 2009; Hoet et al. 2004). 
Many studies have focused on the inhalation 
exposure route for ENMs and have considered 
potential airborne releases of NMs from facili­
ties. After intake of NP­containing aerosols, 
high deposition fractions in the alveo  lar region 
(for particles < 100 nm in size) and the head 
region (diameter < 5 nm) are predicted by the 
multiple­path particle dosimetry (MPPD) and 
International Commission on Radiological 
Protection (ICRP) models (U.S. EPA 2009). 
NM exposure of the lung parenchyma is of 
concern because of long­term retention in 
this lower region and potential for particles to 
cause cytotoxicity and translocate.
General Approach
The aim of this study was to use information 
on potential ENM exposure in the occupa­
tional setting to recommend in vitro testing 
levels for bioprofiling in U.S. EPA ToxCast 
program. Our general approach (Figure 1) was 
to assume that the inhalation exposure route 
for NMs is of primary concern for humans in 
occupational settings. Occupational aerosol 
levels of NMs reported in the litera  ture were 
reviewed and used as inputs for lung dosimetry 
modeling. We assumed that these reported 
NM concentrations from manufacturing and 
R&D laboratory facilities would provide a 
high­end potential for real­world NM exposure 
to the general population, higher than expo­
sures that may result from consumer products 
(Bergamaschi 2009).
We used the maximum reported NM aero­
sol concentrations (mass per cubic meter of air) 
as an input for the MPPD model to estimate 
deposition, clearance, and mass retained in the 
alveo  lar region of the human lung. A sensitiv­
ity analysis was performed to evaluate MPPD 
input parameters that most affect NM alveolar 
retention after 24 hr of exposure. Two expo­
sure scenarios were considered for further mod­
eling: exposure over the course of 24 hr (based 
on the standard assay exposure duration) and 
45 years (a full occupational lifetime). For each 
scenario, we varied the significant parameters 
to estimate the mass of particles retained in the 
alveolar region per surface area. Model results 
of lung surface mass concentrations were then 
converted (using the reported well­bottom sur­
face area and volume delivered) to suggest test­
ing solution mass concentrations for in vitro 
screening. All of the applied material was 
assumed to deposit on the bottom of the well. 
The results suggest upper and lower bounding 
HTS assay testing concentrations based on 
potential for real­world NM exposures at short 
and long durations via the inhalation route in 
an occupational setting. The concentrations 
were subsequently compared with in vitro con­
centrations found in recent literature. Although 
we have chosen here to consider aerosol mass 
concentration, we recognize that other lung 
deposition metrics (based on particle num­
ber or particle surface area) are also potentially 
important for understanding health risk.
A small fraction of NPs deposited in the 
alveolar region may be cleared into the blood­
stream by absorption. Particles that deposit 
in the respiratory tract can also be cleared to 
the gastro  intestinal (GI) tract via the pharynx 
or to the regional lymph nodes (LN) via lym­
phatic channels. Only lung surface cells would 
receive the same concentration of NPs as esti­
mated here for inhalation. Modeling expo­
sure to other cell types is beyond the scope of 
this article, but the concentrations from these 
exposures would likely be significantly lower 
than those calculated for lung cells.
Data and Methods
NM air concentrations. We reviewed occu­
pational exposure studies that meas  ured air­
borne levels of ENMs. The instruments used 
to obtain particle number concentrations 
were typically the condensation particle coun­
ter (CPC), scanning mobility particle sizer 
(SMPS), and the fast mobility particle sizer 
(FMPS). In some cases, personal air samplers 
collected NPs on filters from the breathing 
zone of workers during the work day. The 
SMPS and FMPS instruments provide real­
time temporal changes in particle size. The 
data give particle number concentrations 
(particles per cubic centimeter of air) versus 
particle diameter across the size distribution. 
The CPC provides particle number concentra­
tion (particles per cubic centimeter of air) for 
particles in the range of 2.5 to > 1,000 nm. 
Figure 1. General approach for recommending in vitro testing levels, considering exposure to NMs from 
occupational-setting indoor air via the inhalation route resulting in respiratory tract uptake. Estimated 
exposure potential is converted to levels for NM testing in HTS cellular assays.
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The instruments can also report the change 
in particle number concentration versus time. 
We searched for the highest aerosol parti­
cle number concentrations for TiO2 and Ag 
NPs and for CNTs (including MWCNTs) in 
manufacturing and R&D settings (Table 1). 
Background particle number concentrations 
were subtracted from the maxi  mum particle 
number concentrations if they were reported. 
Typically, particle counts per volume (cubic 
centimeters) of air are reported, whereas 
exposure limits are set as mass concentrations 
(milli  grams per cubic meter). To convert 
from reported particle count concentration to 
mass concentration, TiO2 and Ag NPs were 
assumed to be spherical, and the reported 
size (taken to be geometric particle diameter) 
was used to calculate a particle volume. The 
CNTs were assumed to be cylindrical, and 
reported diameter and length were used to 
obtain particle volume. We assumed a CNT 
length of 0.5 μm if it was not reported. A 
density of 4, 10, and 2 g/cm3 was assumed 
for TiO2 NPs, Ag NPs, and CNT, respec­
tively, based on specifications of similar mate­
rials from supplier web sites (Nanostructured 
& Amorphous Materials Inc. 2010; Sigma­
Aldrich 2010). The high­end reported particle 
counts were approximated to mass concentra­
tions by multiplying particle volume by the 
assumed density (Table 1).
The calculated mass concentrations were 
typically less than approximately 0.1 mg NM 
per volume (cubic meters) of air (Table 1). 
One study on MWCNTs reported a higher 
mass concentration of 0.3208 mg/m3 (Lee 
et al. 2010). However, this value was from 
personal sampler filters with typical sampling 
durations of 183–409 min. The mass concen­
tration would be lower if calculated over the 
time duration. Data normalized over expo­
sure characterization duration from a liquid­
phase production facility of Ag NPs yielded a 
mass concentration of 0.46 mg/m3 for 1 min 
(Park et al. 2009). In that study, both change 
in particle number concentration versus time 
and total number of particles (with diame­
ters between 10 and 250 nm) counted over 
a range of time were reported. A conserva­
tive aerosol concentration of 1 mg/m3 was 
taken to be an upper exposure limit. Although 
the U.S. National Institute for Occupational 
Safety and Health (NIOSH) does not have 
a recom  mended exposure limit (REL) for 
TiO2 NPs, a draft NIOSH bulletin (NIOSH 
2005) recommended “0.1 mg/m3 for ultra­
fine TiO2, as time­weighted average concen­
trations (TWA) for up to 10 hr/day during 
a 40­hour work week,” where “ultrafine” is 
defined as the fraction of respirable particles 
with primary particle diameter < 100 nm. 
A recent draft NIOSH bulletin (NIOSH 
2010) proposed a REL of 0.007 mg/m3 for 
CNTs and carbon nano  fibers. Using a differ­
ent approach, an occupational exposure limit 
of 0.05 mg/m3 was derived for Baytubes, a 
more flexible MWCNT type (Pauluhn 2010). 
There is no limit set for Ag NPs in the United 
States. However, the Occupational Safety 
and Health Administration (OSHA) estab­
lished a permissible exposure limit (PEL) of 
0.01 mg/m3 (which is the same as the REL 
set by NIOSH) for all forms of airborne Ag 
(Miller et al. 2010). The American Conference 
of Governmental Industrial Hygienists 
(ACGIH) set a threshold limit value (TLV) 
of 0.1 mg/m3 for metallic Ag and 0.01 mg/m3 
for soluble Ag compounds (Miller et al. 2010). 
In the present study, the mass concentrations 
derived based on meas  ured aerosol levels were 
taken as a basis and used as inputs to model 
the mass of NPs that could deposit and be 
retained deep in human lungs.
Lung dosimetry modeling. MPPD model 
application. We estimated particle deposi­
tion and clearance in human lungs using the 
recently developed, publicly available MPPD 
model (version 2.1 for NPs, presently sup­
ported by Applied Research Associates Inc., 
Raleigh, NC). The model can be used to esti­
mate particle dosimetry in both human and 
rat airways (Anjilvel and Asgharian 1995; 
Asgharian et al. 2001). It calculates deposi­
tion and clearance of particles ranging from 
ultrafine (0.001 μm) to coarse (100 μm) in 
the respiratory tract, based on user­provided 
input on airway morphometry, clearance rates, 
particle properties (density, diameter, and size 
distribution), and exposure scenario (aerosol 
concentration, activity breathing pattern, and 
exposure duration). Three main particle depo­
sition mechanisms (impaction, sedimentation, 
and diffusion) are incorporated in the model, 
and deposition in different regions of the lung 
are calculated using published analytic formu­
las (Anjilvel and Asgharian 1995). Clearance 
from each lung region is treated competitively 
between absorption into the blood and par­
ticle transport processes (from the respiratory 
tract to the GI tract and to lymph nodes, and 
from one region to another) (ICRP 1994). 
Retention in the human alveolar­interstitial 
region is represented by three compartments, 
which clear at fast, medium, and slow rates 
to the lymph nodes and the bronchiolar 
region (ICRP 1994). Although the clearance 
kinetics in the MPPD model were based on 
studies of micro  sized particles, evidence sug­
gests efficient surface macrophage uptake and 
clearance of both microparticles and NPs as 
well as penetration of both sizes of particles 
through the human lung epithelium into the 
interstitial region, from which they are slowly 
cleared (Geiser and Kreyling 2010). In addi­
tion, the MPPD model (version 2.1) incor­
porates improved estimates of particle losses 
from the airway by diffusion and includes 
particle­specific axial diffusion and dispersion 
effects in the transport equation (Asgharian 
Table 1. NM exposure concentrations in lab and manufacturing sites.
NM Highest particle count (no./cm3) Mnfg/lab Particle size (nm)
Calculated mass  
concentration (mg/m3)
Instrument used 
for detection Reference
Ag NPs 72,900 Mnfg 35 0.02 CPC Methner et al. 2010a, 2010b
1.102 × 107 (for 55 min) Mnfg 76 0.46 (for 1 min) SMPS Park et al. 2009
7,000 Lab 150 0.12 FMPS Tsai et al. 2009
995,000 (for 15–30 min) Mnfg 10 0.005 FMPS Miller et al. 2010
0.094 (for full work shift) Personal filter 
sample [0.01 (OSHA PEL; airborne Ag)]
MWCNTs 35,800 R&D Lab 20 nm diameter, 
0.5 μm length
0.01 CPC Methner et al. 2010a, 2010b
— — — [0.05 (researcher-suggested OEL)] — Pauluhn 2010
75,000; during metal catalyst 
preparation
Mnfg –  
seven sites
25 nm diameter, 
no reported length
0.037 SMPS Lee et al. 2010
0.32 Personal air
CNTs 7,000; no detectable CNTs or bundles Lab 10 and 100 diameter 0 FMPS and CPC Bello et al. 2008
5,000,000 (CNT carbon composites; 
no detectable CNTs or bundles)
R&D Lab — 0 FMPS Bello et al. 2009
— — — 0.007 (draft REL for elemental carbon) — NIOSH 2010
TiO2 NPs 111,300 Mnfg 40 0.015 CPC Methner et al. 2010a, 2010b
— — — 0.1 (draft REL) — NIOSH 2005
140,000 Mnfg 16 0.001 SMPS Hameri et al. 2009
Abbreviations: Mnfg, manufacturing; OEL, occupational exposure limit.Gangwal et al.
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and Price 2007). This updated model provides 
for more realistic assessment of regional depo­
sition of diffusion­dominated (nano  sized) par­
ticles in the lung (Asgharian and Price 2007). 
A MPPD model version (obtained directly 
from Applied Research Associates, Inc.) that 
incorporates length­to­diameter aspect ratio to 
predict inhaled nanofiber/nanotube deposition 
in the human lung was used for non  spherical 
CNTs/MWCNTs (NIOSH 2008). This 
model incorporates altered analytical expres­
sions for deposition efficiency of nano  fibers of 
a given aspect ratio by adjusting for the viscous 
drag and nano  fiber orientation in the deposi­
tion efficiency equation for spherical particles. 
The clearance calculations are valid only for 
spherical particles.
We selected an initial baseline set of 
MPPD inputs (Table 2) based on data from 
the ICRP report (ICRP 1994), which provided 
morphological charac  teristics and physio­
logi  cal parameters for the human respiratory 
tract. We organized the MPPD model input 
parameters into three categories: individual 
characteristics, exposure scenario, and mate­
rial properties. For the individual characteris­
tics input, the airway morphometry selected 
was the human Yeh/Schum symmetric lung 
model (Yeh and Schum 1980). Default val­
ues were selected for the clearance rates and 
other parameters. For the exposure scenario 
input, 0.1 mg/m3 aerosol concentration was 
selected, and light exercise activity breathing 
pattern for an adult male was assumed with 
20 breaths/min frequency at 1,250 mL tidal 
volume, (VT) (ICRP 1994). Oronasal­mouth 
breather was selected for breathing scenario, 
because humans typically switch to breathing 
partly through the mouth and through the 
nose at ventilation rates between light and 
heavy exercise (ICRP 1994). For the particle 
properties input, we selected a particle count 
median diameter of 40 nm, assuming a single 
mode of log­normal size distribution with size 
geometric standard deviation (GSD) of 1.25 
based on the ICRP report. Inhalability was 
not considered because it approaches 100% 
for small (< 5 μm) particles (ICRP 1994). The 
length­to­diameter aspect ratio was set to 1.
Sensitivity analysis. Key determinants of 
MPPD model predictions of mass (milli  grams) 
retained in the alveolar region were determined 
by systematically altering each input baseline 
parameter one at a time, while holding the oth­
ers constant, and rerunning the model based on 
a 24­hr exposure duration with 1 week of total 
time (Table 3) to allow for clearance. For the 
individual charac  teristic inputs, we evaluated 
two different size (based on total number of 
airways) human stochastic lung models because 
they provide more realistic lung geometry than 
the symmetric lung model. Calculations were 
also performed using an age­specific symmetric 
lung model for a 3­year­old child. Although 
this group is unlikely to be exposed occupa­
tionally, we wanted to check model results for 
a vulnerable population group. The alveolar 
interstitial rate constants for fast, medium, 
slow, and lymph node human clearance were 
doubled, halved, increased by an order of 
magnitude, and decreased by an order of mag­
nitude. Tracheal mucosal velocity was not con­
sidered because it affects only tracheo  bronchial 
clearance rates and residence times and will not 
affect long­term alveolar burden. For the expo­
sure scenario inputs, the aerosol concentra­
tion was decreased by one order of magnitude 
from 0.1 mg/m3. As a conservative estimate in 
case the mass per air volume concentration was 
much higher than reported, the aerosol mass 
concentration was also increased by one and 
two orders of magnitude. Both heavy­exercise 
and resting breathing patterns were evaluated, 
as well as purely nasal and oral breathing. For 
the particle properties inputs, we considered a 
low size diameter of 5 nm, a high diameter of 
100 nm, a low GSD of 1 (monodisperse diam­
eter distribution), and a high GSD of 4 (poly­
disperse diameter distribution). Additionally, 
aspect ratios from 4 to 1,000 were evaluated 
with a length GSD of 1.0 (as a conservative 
estimate) and a density of 2.
For this sensitivity analysis, if the alveo  lar 
mass retained using the new setting resulted 
in a percentage change ≥ 10% of the baseline 
amount, the parameter was considered to be 
significant and was evaluated further. If the 
alveolar mass retained using the new setting 
yielded a negative percentage change com­
pared with the baseline setting, then the input 
was not considered, because we are interested 
in a conservative exposure approach that may 
over  estimate particle deposition and retention 
deep in the lungs. If alveolar retention output 
did not change linearly with change in input, 
additional input changes were considered to 
better characterize model behavior over the 
relevant range. The MPPD input parameters 
determined to be significant were evaluated 
further to calculate mass retained in the alveo­
lar region per alveolar surface area, based on 
two exposure durations: a short­term exposure 
duration of 24 hr and a long­term occupa­
tional lifetime exposure. The long­term sce­
nario assumed a 45­year full working lifetime 
(Schulte et al. 2010) with 8 hr inhalation per 
day, 5 days/week, 52 weeks/year. The alveolar 
surface area (~ 106,350 cm2) was obtained 
from the MPPD model results report by sum­
ming the pulmonary surface area for lung gen­
erations 17 to 24. This alveolar surface area 
accounts for only surface area of the airways 
(alveolar ducts) and not the alveolar sacs, and 
thus is a low estimate of the actual alveolar 
surface area. The MPPD calculations were 
performed for different particle sizes (5, 10, 
20, 30, 40, 50, 60, 70, and 100 nm), aerosol 
concentrations (0.1 and 1 mg/m3), and expo­
sure durations. Larger particle sizes (200, 500, 
and 1,000 nm) were also run because particle 
aggregation of nano  sized particles may occur 
in air (Maynard et al. 2004; Methner et al. 
2010a) or inside the human respiratory tract. 
For CNTs, an aspect ratio of 167 was selected 
based on material dimensions (5 μm length, 
30 nm diameter) of one sample to be tested 
in ToxCast. Aspect ratios of 2, 4, and 10 were 
also run for the different particle sizes. These 
aspect ratios were chosen based on electron 
images of SWCNT aggregates from the litera­
ture (Baron et al. 2008). Searching for realistic 
airborne CNT aspect ratios was challenging 
because many exposure studies found no evi­
dence of carbon­based nano  tubes or nano  tube 
bundles in air samples (Bello et al. 2008, 
2009). In one study of seven CNT­handling 
workplaces, transmission electron micrographs 
reveal clumped structures with aspect ratios of 
approximately 8–10 and diameters of approxi­
mately 100 nm (Lee et al. 2010). However, 
these particle aggregates are mostly metal com­
ponents rather than CNTs.
Determining in vitro concentrations. Based 
on MPPD model predictions, we determined 
associated in vitro concentrations by calculat­
ing mass retained in the alveolar region of the 
lung per alveolar surface area for each particle 
size, at two aerosol concentrations (0.1 and 
Table 2. MPPD baseline settings.
MPPD baseline input categories Baseline input settings
Individual characteristics (airway 
morphometry and deposition/clearance)
Human species; Yeh-Schum symmetric single path lung model; 
FRC = 3,300 mL; URT volume = 50 mL
Tracheal mucous velocity = 5.5 mm/min; fast human clearance 
rate = 0.02/day; medium human clearance rate = 0.001/day; slow 
human clearance rate = 0.0001/day; lymph node human clearance 
rate = 0.00002/day 
Exposure scenario: constant exposure Acceleration of gravity = 981.0 cm/sec2; body orientation = upright; 
aerosol concentration = 0.1 mg/m3; breathing frequency = 20/min; 
VT = 1,250 mL; inspiratory fraction = 0.5; pause fraction = 0; breathing 
scenario, oronasal-mouth breather; number of hours per day = 24; 
number of days per week = 1; number of weeks = 1; maximum 
postexposure days = 0
Particle properties Density = 4 g/cm3; diameter = 0.04 μm; count median diameter 
checked; NP model checked; inhalability adjustment not checked; 
GSD (diameter) = 1.25
Abbreviations: FRC, functional residual capacity; URT, upper respiratory tract.In vitro nanomaterial concentration selection
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 11 | November 2011  1543
1 mg/m3) and for each exposure scenario 
(24 hr and 45 years). We assumed that the 
NM mass retained at the lung surface can be 
directly correlated to NM mass sedimented 
on the bottom surface of a well. To convert to 
mass of NM per volume of solution, we mul­
tiplied the resulting mass per alveolar surface 
area concentration (micrograms per square 
centimeter) by the bottom surface area of a 
single well in a 12­, 96­ or 384­well plate and 
divided by the volume of culture medium 
added to each well (as obtained from the 
assay contractors). The 12­, 96­, and 384­well 
plates had a single well­bottom surface area 
of 3.8, 0.32, and 0.056 cm2 and volume of 
1,000, 200, and 50 μL, respectively. The con­
verted concentrations were compared with 
in vitro concentrations tested using human, 
mouse, and rat cell lines in the litera  ture [see 
Supplemental Material, Tables S1–S3 (http://
dx.doi.org/10.1289/ehp.1103750)]. Although 
final selection of concentration will include 
consideration of the MPPD model output 
and conversion, there will still be a need to test 
at levels based on where bioactivity has been 
demon  strated in the literature, bounded by 
concentration levels that can be dispersed with 
long­term stability in cell culture media.
Another method to determine high range 
in vitro concentrations to test could be to eval­
uate a NM steady­state mass in the alveo  lar 
region of the lung. Steady state occurs when 
the clearance rate equals the rate of deposition 
and the NM mass retained reaches a constant 
value. According to Brown et al. (2005), it 
takes > 10 years to reach a steady­state lung 
burden for insoluble 1 μm­sized particles for 
a 0.01­mg/m3 aerosol concentration based on 
resting human breathing pattern. 
Results and Discussion
Key MPPD model input parameters. For the 
MPPD baseline settings used here (Table 2), 
a steady­state retention dose would take 
> 80 years to achieve for 40­nm particles 
based on inhalation of an aerosol concentra­
tion of 0.1 mg/ m3 for 8 hr/day, 5 days/week. 
Because of the long time to achieve steady 
state, we did not use that method. Instead, 
we focused on modeling potential exposure 
scenarios and under  standing implications of 
associated model inputs. Model results for the 
baseline input parameters (Table 2) resulted in 
1.22 mg alveolar mass retained.
Results of the sensitivity analysis [alveolar 
mass retained, percentage change in model 
output and input, and sensitivity percent­
age (output percentage change by input per­
centage change)] are presented in Table 3. 
Although inter  actions between input param­
eters may occur, we assumed that key param­
eters could be uncovered by varying one 
parameter per run. Based on this analysis, 
aerosol concentration and heavy­exercise 
breathing pattern were the most important 
MPPD input parameters, as these increased 
alveolar retention by > 10%. For variations 
to the inputs for individual characteristics 
(Table 3), the choice of airway morphometry 
using the the human stochastic lung model 
resulted in a lower retention compared with 
the symmetric lung model. The age­specific 
symmetric lung model for a 3­year­old child 
resulted in lower mass retained at 0.16 mg 
because of lower intake (functional residual 
capacity, upper respiratory tract volume, and 
VT) compared with the adult male default 
baseline condition. Thus, the Yeh/Schum 
symmetric model provided a conservative esti­
mate of NM particle dosimetry. Nasal and 
oral breathing scenario did not significantly 
affect the results and was set to the baseline of 
oro  nasal breathing. Increasing and decreasing 
the default alveolar­interstitial rate constants 
did not significantly affect the result as indi­
cated by the sensitivity percentage in Table 3. 
The alveolar­interstitial rate constants were set 
to the default values and the lung model to 
symmetric to further calculate alveolar mass 
retained per alveolar surface area.
For the exposure scenario inputs (Table 3), 
the correlation between alveolar mass retained 
and aerosol concentration was linear: The 
amount retained in the alveolar region changed 
linearly by one order of magnitude as the expo­
sure aerosol concentration (and thereby the 
intake) was increased or decreased by one order 
of magnitude, yielding a sensitivity of 100%. 
Using resting or heavy­exercise breathing pat­
tern resulted in a sensitivity of approximately 
100%, indicating that alveolar mass retained 
changed almost linearly with minute ventila­
tion (breathing frequency by VT). To further 
calculate alveolar mass retained per alveolar 
surface area, the breathing scenario was set to 
light exercise, based on the assumption that 
this was the most realistic for a full working 
lifetime. The aerosol concentration of 1 mg/m3 
was taken as a conservative estimate of poten­
tial worker exposure.
Table 3. MPPD sensitivity analysis.
MPPD input 
category Altered input setting
Output 
alveolar mass 
retained (mg)
Percent 
change 
in output
Percent 
change 
in input
Sensitivity 
percent
Individual 
characteristics
Human, stochastic lung model
1st size percentile 0.81 –34.1 — —
60th size percentile 1.01 –17.2 — —
Age-specific symmetric model:
3-year-old child 0.16 –87.1 — —
Clearance rates
0.1 × default alveolar-interstitial rate constants 1.27 3.8 –90 –4.18
0.5 × default rate constants 1.25 2.0 –50 –4.09
1.5 × default rate constants 1.20 –2.0 50 –3.92
2 × default rate constants 1.18 –3.8 100 –3.76
10 × default rate constants 0.95 –23.0 900 –2.50
Exposure 
scenario
Aerosol concentration
0.01 mg/m3 0.12 –90.0 –90 100
1 mg/m3 12.2 898 900 99.7
10 mg/m3 122.3 9,900 9,900 100
Breathing pattern
Resting, 12 breaths/min; 625 mL VT 0.32 –74.1 –70 106
Heavy exercise, 26 breaths/min; 1,923 mL VT 2.30 88.0 100 88.0
Breathing scenario 
Nasal 1.20 –2.1 — —
Oral 1.25 2.0 — —
Particle 
properties
Diameter
5 nm 0.81 –33.9 –87.5 38.7
20 nm 1.51 23.5 –50 –46.9
50 nm 1.07 –12.7 25 –50.7
70 nm 0.85 –30.7 75 –41.0
100 nm 0.65 –46.6 150 –31.1
GSD
1 1.33 9.08 –20 –45.4
1.6 0.90 –26.7 28.0 –95.5
2 0.60 –51.2 60 –85.3
2.8 0.68 –44.3 124 –35.7 
4 0.12 –90.1 220 –41.0
Aspect ratio (length:diameter)
1 (Baseline) (20 nm:20 nm) 1.54 0 0 —
4 (80 nm:20 nm) 1.26 –18.3 300 –6.09
20 (400 nm:20 nm) 1.56 1.69 1,900 0.09
100 (2 μm:20 nm) 1.12 –27.3 9,900 –0.28
500 (10 μm:20 nm) 0.61 –60.1 49,900 –0.12
1,000 (20 μm:20 nm) 0.54 –65.0 99,900 –0.07
—, not applicable.Gangwal et al.
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Particle property input changes to par­
ticle diameter, size GSD, and aspect ratio 
(length:diameter) did not result in linear 
changes to output alveolar mass retention, as 
observed in the sensitivity percent column in 
Table 3. Particle diameter of 20 nm resulted in 
maximum alveolar mass retained of 1.51 mg 
for diameters between 5 and 100 nm and was 
approximately 24% increase in output com­
pared with baseline 40 nm size. A GSD value 
of 1 (mono  disperse size distribution) yielded a 
higher mass amount retained, but it was only 
9.08% more than the baseline­size GSD value 
of 1.25 and did not meet the sensitivity analy­
sis requirements. All other input changes for 
diameter and GSD lowered the alveolar mass 
retained compared with the baseline settings. 
In a report on TiO2 particles, Hameri et al. 
(2009) listed a GSD of 1.66, and in a study 
of Ag NPs, Park et al. (2009) listed GSD val­
ues of 4.63–6.3. Although a higher­size GSD 
value is expected for realistic size distribution 
of NMs, this parameter was set to 1.25 as 
a conservative estimate that would increase 
alveolar retention. Changes to the aspect ratio 
input at constant aerosol concentration and 
minute ventilation lowered the alveolar mass 
retained compared with the baseline (aspect 
ratio 1 in Table 3). Only an aspect ratio of 20 
slightly increased the alveolar mass retained. 
The sensitively percent to the aspect ratio 
parameter was low.
Concentrations recommended for in vitro 
testing. In Figure 2, results of the deposition 
modeling are presented as a function of mate­
rial charac  teris  tics for the two exposure sce­
narios of interest. Because MPPD alveolar 
mass retention was linearly proportional to 
the inputted aerosol concentration, we plot­
ted mass per lung surface area per inputted 
aerosol concentration versus particle diam­
eter. The alveolar retention per surface area 
for Ag and TiO2 spherical NPs for a full 
working lifetime was highest for 20­nm diam­
eter particles (48.9 μg/cm2), based on an 
exposure aerosol concentration of 1 mg/m3 
(Figure 2A). Relative to this peak lung sur­
face concentration, the amount decreased to 
20.3 μg/cm2 as size was increased to 100 nm, 
and also decreased to 25.1 μg/cm2 for 5­nm 
particles. For the 12­, 96­ and 384­well plates 
used by the different assay contractors, the 
peak lung surface concentration equates to 
186 [i.e., 48.9 μg/cm2 × (3.8 cm2/mL)], 78.2, 
and 54.8 μg/mL, respectively. These amounts 
for a full working lifetime lie within the range 
of the highest in vitro assay concentrations 
tested in the literature for Ag NPs and TiO2 
NPs on human, rat, and mouse cell lines. The 
highest amount tested for Ag NPs ranges from 
1.6 to 500 μg/mL, whereas for TiO2 NPs, 
the high­side range is 100–1,000 μg/mL or 
20–520 μg/cm2 [see Supplemental Material, 
Tables S1and S2 (http://dx.doi.org/10.1289/
ehp.1103750)]. Concentrations for most 
of the Ag NPs tested fell within 50–400   
μg/mL, whereas those for TiO2 NPs fell 
within 100–250 μg/mL. Because the MPPD 
model uses a low estimate of alveolar surface 
area, a more realistic estimate would result 
in lower alveolar mass retained per surface 
area (by approximately one order of magni­
tude), which would correspond to a lower 
in vitro concentration for a given exposure 
duration. For a full working lifetime exposure 
duration to 0.1 mg/m3, the peak lung surface 
concentration was 4.9 μg/cm2 (for particles 
with a diameter of 20 nm) and the range was 
2.0–4.9 μg/cm2 for particle with diameters 
of 5–100 nm (Figure 2A). Because alveolar 
retention is directly proportional to aerosol 
concentration, reducing the input aerosol 
concentration by a factor of 10 results in a 
linear reduction of the calculated well­plate 
concentration (micrograms per milli  liter) by 
a factor of 10. The calculated well­plate con­
centration for a full working lifetime is similar 
to the low range (1.6–10.8 μg/mL) of the 
highest concentrations tested in in vitro assays 
for Ag NPs, but it is below the range tested 
for TiO2 NPs [see Supplemental Material, 
Tables S1 and S2 (http://dx.doi.org/10.1289/
ehp.1103750)].
The lung surface concentration for a 24­hr 
exposure duration to 1 mg/m3 aerosol con­
centration of TiO2 or Ag NPs ranged from 
0.061 to 0.15 μg/cm2 for particles 5–100 nm 
in diameter (Figure 2A). This range is more 
than two orders of magnitude lower than the 
range for a full working lifetime (Figure 2A). 
The peak lung surface concentration equates 
to 0.570, 0.240, and 0.168 μg/mL for the 
12­, 96­ and 384­well plates, respectively. In 
previous studies, the lowest amount tested 
for Ag NPs ranged from 0.108 to 25 μg/mL 
[see Supplemental Material, Table S1 (http://
dx.doi.org/10.1289/ehp.1103750)], whereas 
for TiO2 NPs the range was 0.002–10 μg/mL   
or 0.0052–5 μg/cm2 (see Supplemental 
Material, Table S2). For 24­hr exposure dura­
tion, the alveolar surface concentrations calcu­
lated using the MPPD model fell within the 
range (closer to the lower end) of the lowest 
in vitro concentrations tested. Thus, the con­
centrations reported in previous studies (see 
Supplemental Material, Tables S1 and S2) are 
similar to the lower­bound assay test concen­
trations we derived using the estimated lung 
retention after 24 hr exposure. Each of the 
studies had a set exposure duration ranging 
from 1 to 144 hr for Ag NPs and from 5 min 
to 120 hr for TiO2 NPs (see Supplemental 
Material, Tables S1 and S2). Rerunning all 
the baseline settings for 20­nm particles for 
24­hr exposure duration would require a very 
high aerosol concentration of approximately 
330 mg/m3 to result in a similar peak alveolar 
surface concentration (~ 48.9 μg/cm2) for 
TiO2 and Ag NPs.
Results of the present study show that 
the alveolar mass retention per surface area 
for CNTs (with a length­to­diameter aspect 
ratio of 167) for a full working lifetime expo­
sure to 1 mg/m3 aerosol concentration ranged 
from 12.4 to 46.5 μg/cm2 (Figure 2B), similar 
to the range for spherical particles. As CNT 
diameter decreased from 100 nm, the mass 
retained per surface area increased to a maxi­
mum of 46.5 μg/cm2 for 5­nm diameter nano­
tubes. In previous studies, the highest amount 
tested in vitro for CNTs ranged from 50 to 
1,000 μg/mL [see Supplemental Material, 
Table S3 (http://dx.doi.org/10.1289/
ehp.1103750)]. Most of the CNT concen­
trations tested fell within 50–400 μg/mL. 
For the more realistic aspect ratios of 4 and 
10, we observed peak mass per surface area 
concentration at 40 nm and approximately 
25 nm, respectively (Figure 2B). This peak 
concentration decreased with increasing diam­
eter (Figure 2B). It is possible that the CNTs 
will form aggregates of larger diameter and 
lower aspect ratios, as reported by Baron et al. 
(2008). Using the model, we observed that 
Figure 2. MPPD model results of alveolar mass retained per alveolar surface area per inputted aerosol 
concentration versus particle diameter in human lungs for (A) TiO2 and Ag NPs with exposure durations of 
45 years (full working lifetime) and 24 hr, and (B) CNTs with aspect ratios of 167, 10, 4, and 2 after 45 years of 
exposure. Both A and B are based on a light exercise breathing pattern. The curves are to guide the eye.
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particles with aspect ratios of approximately 
20 had a maximum deposition fraction in 
the alveolar region. For the aspect ratios 2, 4, 
and 10, the mass per surface area retained for 
diameters > 40 nm followed a similar trend. 
The lung surface concentration of aspect 
ratio 2 was similar to the trend for spherical 
particles (Figure 2A) at the same aerosol con­
centration and exposure duration.
Applications of approach. The approach 
we took in this study was a simple screening­
level assessment using the latest quantitative 
NM aerosol data in occupational settings to 
determine concentrations that may deposit 
and be retained deep in the human respiratory 
tract. The methodology we used and the alveo­
lar retention results obtained can be generally 
applied to inform in vitro study designs, which 
include other NM types. Wherever possible, 
conservative MPPD input parameters were 
selected so that results would indicate a higher 
alveolar retention, although we attempted to 
choose realistic inputs as well. Our results indi­
cate that a full lifetime occupational exposure 
to a concentration of 1 mg/m3 (one order of 
magnitude higher than what has typically been 
reported) (Table 1) is required to reach the 
highest concentrations currently being tested 
in vitro in most studies [see Supplemental 
Material, Tables S1–S3 (http://dx.doi.
org/10.1289/ehp.1103750)]. Because in vitro 
studies use different cell culture containers, in 
order to convert the lung surface concentra­
tions provided here, the specific well­bottom 
surface area and medium volume presented to 
each well are required.
Note that we are comparing lung surface 
concentrations to concentrations being tested 
in a range of cell types and would expect only 
a small percentage of particles to reach cells 
in other organs of the body following absorp­
tion into the bloodstream. Nevertheless, 
retention of NPs in the deep lung alveolar 
region is important because these particles 
potentially can be absorbed quickly into the 
bloodstream. Such a phase of rapid absorp­
tion is observed immediately after inhala­
tion, even with relatively insoluble materials 
(ICRP 1994). Recently, in a study in rats, 
Choi et al. (2010) found a) that NPs with 
hydro  dynamic diameters < 6 nm and zwit­
terionic surface charge can rapidly enter the 
bloodstream from the lung and then be sub­
sequently cleared by the kidneys; and b) that 
NPs < 34 nm with a non  cationic surface 
charge translocate rapidly from the lung to 
the media  stinal lymph nodes. However, for 
technetium­radiolabeled 100­nm, 35­nm, and 
4–20­nm diameter carbon particles, no sig­
nificant systemic translocation of particles has 
been observed in humans (Mills et al. 2006; 
Möller et al. 2008; Wiebert et al. 2006). Gold 
NPs (5–8 nm) have been found at a low frac­
tion (0.03–0.06% of lung concentration) in 
the blood of rats 1–7 days after inhalation 
(Takenaka et al. 2006). The type and amount 
of surface charge or coating may be a key fac­
tor for trans  location of particles and should 
be evaluated. There is also a potential for 
larger mass amounts of NMs per lung surface 
area to be deposited in the tracheobronchial 
region. All airway surfaces may not receive the 
same amount of deposited particles, and local­
ized hot spots for deposition in the vicinity of 
airway bifurcations have been predicted (up to 
100–1,000 times higher than the average mass 
per surface area for particles > 10 nm) using 
mathematical modeling techniques (Farkas 
et al. 2006; U.S. EPA. 2009). However, we 
did not consider mass retained in this region 
because a large portion of the particles depos­
ited is assumed to be cleared within 24–48 hr 
by action of the mucociliary escalator (U.S. 
EPA 2009). Potential future work will con­
sider GI tract exposure to NPs cleared from 
the tracheo  bronchial region because it may 
be significant for aggregated NPs at heavy­
exercise breathing conditions.
Limitations of approach. There are several 
limitations in estimating concentrations for 
in vitro testing using the latest available NP 
aerosol­level data from occupational settings. 
The instrumentation technology to measure 
spherical NPs typically provides non  specific 
particle counts over a broad size range. For 
example, the SMPS provides particle counts 
in a size range of 2.5–1,000 nm, whereas the 
CPC used in several studies (Table 1) measures 
particles 10–1,000 nm. Particle counts become 
increasingly insensitive to particle sizes that are 
nearer to the lower limit of detection (Maynard 
and Aitken 2007). Measurements for non­
spherical particles such as CNTs may not be 
reliable and may need to be corrected because 
these instruments are designed to count spheri­
cal particles. Additionally, to compare particle 
number concentration for the same type of 
materials across different occupational set­
tings or manufacturing processes, the FMPS 
and SMPS data reported need to be normal­
ized by dividing by the number of channels. 
Instrument data are not always normalized and 
thus may be reported as a higher count over 
a particle size distribution than what actually 
occurs. It is not currently possible to distin­
guish between NPs, aggregates of the same 
compounds, and aggregates of a mixture of par­
ticles, dust, and other airborne particle types. 
NPs often can agglomerate in air, which is why 
we present results for potentially more realistic 
sizes > 100 nm (Figure 2A,B). Instruments 
such as the universal NP analyzer (UNPA), 
which uses a CPC, a differential mobility ana­
lyzer (DMA), and an NP surface area monitor 
(NSAM) are being developed to determine the 
primary particle size and measure the num­
ber, surface area, and volume distributions 
of gas­borne NP agglomerates (Wang et al. 
2010). To distinguish NPs from background 
particles, both real­time instrumentation meas­
ure  ments and qualitative analysis by electron 
microscopy are required (Ono­Ogasawara 
et al. 2009). In addition, chemical analy  sis is 
necessary for quantitatively assessing exposure 
to NMs at facilities with high levels of back­
ground NPs. Models are being developed to 
predict the change in NP number concentra­
tion for a defined source and a defined envi­
ronment based on a given background aerosol 
concentration (Seipenbusch et al. 2008). NPs 
do not reach the receptor in their original size 
as an aerosol, but change their size and number 
concentration by coagulation either within the 
same type of materials or by inter  action with a 
background aerosol (Seipenbusch et al. 2008).
Here we provide MPPD results in which 
we assumed no changes to the original aero­
sol concentration and performed simulations 
using the reported size of the particles. If parti­
cles have a tendency to aggregate and agglom­
erate above an aggregate size of 100 nm, the 
amount deposited and retained in different 
regions of the lung will be less (Figure 2A,B). 
In the case of SWCNTs, large aggregates 
> 10 μm in diameter can form by diffusion 
and van der Waals inter  actions between nano­
tubes in air or in aqueous solutions (Mutlu 
et al. 2010). Other drawbacks based on the 
method used include limitations with the 
MPPD model, such as a low estimate of 
alveolar surface area. Currently, distinctions 
between NM types cannot be made based 
on NM physico  chemical characteristics. The 
only input possible in the latest version of the 
model is length­to­diameter aspect ratio for 
cylindrical particles. The clearance calculations 
in the model are based on experi  mental data 
for spherical particles, and fibers with elon­
gated structures may have different clearance 
kinetics. NMs have unique physico  chemical 
charac  teris  tics that may affect their deposition, 
retention, and toxicity. These characteristics 
include particle shape and shape distribution, 
large surface area:volume ratio, chemical com­
position and crystalline form, surface compo­
sition and coating, and surface charge. There is 
a need to understand which physico  chemical 
charac  teris  tics most affect the deposition and 
alveolar retention of NPs and to further incor­
porate these key parameters into the model.
Another limitation in the approach may 
be the conversion of lung surface concentra­
tions to in vitro test concentrations, assum­
ing that the NMs will quickly (relative to the 
duration of the assay) settle onto the cells at 
the bottom of the well plate. If the particle 
transport (diffusion, sedi  menta  tion) time is 
slower than the in vitro assay testing time 
(which could possibly be the case for particle 
agglomerates, depending on their mass, size, 
and density) (Hinderliter et al. 2010), then the 
localized NM concentrations near the cells at Gangwal et al.
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the bottom of the well may be lower than we 
estimated. A recently developed computational 
model of partico  kinetics (sedimentation, dif­
fusion) and target cell dosimetry for in vitro 
systems addressed this issue (Hinderliter et al. 
2010) and could be used to calculate dose rates 
and target cell doses to compare with the total 
assay exposure time. Further, bio  activity pro­
files attained for NMs would need to take into 
account the localized concentration. 
Conclusions
Consideration of potential exposures during 
design of in vitro toxicity tests would improve 
interpretation of hazard screening results for use 
in risk assessment. The methodology described 
here is a first step toward improving selection 
of NM concentrations to test in vitro based on 
real­world inhalation exposure potential. The 
results obtained can be generally applied to 
other in vitro study designs and for other NM 
types. The approach here reveals that current 
high­range in vitro testing concentrations being 
used are similar to predicted lung surface area 
concentrations based on inhalation exposure 
to NMs of a high aerosol concentration in an 
occupational setting over the course of a full 
working lifetime. This methodology can be 
improved by better measurements of NMs in 
occupational settings, addition of particle prop­
erty input parameters to the MPPD model, 
and considerations of delivered dose to cells.
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